Other mucoactive agents for cystic fibrosis

Paediatric Respiratory Reviews

Volumn 8, Issue 1, 2007, Pages 30-39

  Bye, Peter T P ^a   Elkins, Mark R ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

agonist; cystic fibrosis; denufosol; hypertonic saline; mannitol

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DENUFOSOL; DORNASE ALFA; EXPECTORANT AGENT; HISTAMINE; ION TRANSPORT AFFECTING AGENT; ISOTONIC SOLUTION; MANNITOL; METHACHOLINE; MUCIN; MUCOKINETIC AGENT; PLACEBO; PURINE P2Y2 RECEPTOR STIMULATING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; RESPIRATORY TRACT AGENT; SALBUTAMOL; SODIUM CHLORIDE; TERBUTALINE; UNCLASSIFIED DRUG; WATER;

CHEST TIGHTNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRY POWDER; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; ION TRANSPORT; LUNG CLEARANCE; LUNG FUNCTION; MUCOCILIARY CLEARANCE; MUCUS SECRETION; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; RESPIRATORY AIRFLOW; RESPIRATORY EPITHELIUM; REVIEW; SINGLE DRUG DOSE; SPUTUM; UNSPECIFIED SIDE EFFECT; WATER TRANSPORT;

CYSTIC FIBROSIS; EXPECTORANTS; HUMANS; ION TRANSPORT; MUCUS;

EID: 34047099736     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2007.02.008     Document Type: Review

References (100)

1. Rubin B.K. Taxonomy of mucoactive medications. In: Rubin B.K., and van der Schans C.P. (Eds). Therapy for mucus-clearance disorders. Lung biology in health and disease vol 188 (2004), Marcel Dekker, New York 129-145
2. Tarran R., Grubb B.R., Gatzy J.T., Davis C.W., and Boucher R.C. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 118 (2001) 223-236
3. Matsui H., Verghese M.W., Kesimer M., et al. Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J Immunol 175 (2005) 1090-1099
4. Brogen T.D. The high molecular weight components of sputum. Br J Exp Pathol 41 (1960) 288-297
5. Lethem M.I., James S.L., Marriott C., and Burke J.F. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J 3 (1990) 19-23
6. Potter J.L., Matthews L.W., Lemm J., and Spector S. Human pulmonary secretions in health and disease. Ann N Y Acad Sci 106 (1963) 692-697
7. Smith A.L., Redding G., Doershuk C., et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 112 (1988) 547-554
8. Boucher R.C. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Del Rev 54 (2002) 1359-1371
9. Donaldson S.H., and Boucher R.C. Update on pathogenesis of cystic fibrosis lung disease. Curr Opin Pulm Med 9 (2003) 486-491
10. Stutts M.J., Canessa C.M., Olsen J.C., et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 269 (1995) 847-850
11. Trout L., King M., Feng W., Inglis S.K., and Ballard S.T. Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus. Am J Physiol 272 (1997) L372-L377
12. Matsui H., Grubb B.R., Tarran R., et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95 (1998) 1005-1015
13. Matsui H., Randell S.H., Peretti S.W., William Davis C., and Boucher R.C. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest 102 (1998) 1125-1131
14. Joris L., Dab I., and Quinton P.M. Elemental composition of human airway surface fluid in healthy and diseased airways. Am Rev Respir Dis 148 (1993) 1633-1637
15. Smith J., Travis S., Greenberg E., and Welsh M. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85 (1996) 229-236
16. Goldman M.J., Anderson G.M., Stolzenberg E.D., Kari U.P., Zasloff M., and Wilson J.M. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88 (1997) 553-560
17. Zabner J., Smith J.J., Karp P.H., Widdicombe J.H., and Welsh M.J. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol Cell 2 (1998) 397-403
18. Bals R., Wang X., Wu Z., et al. Human β-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 102 (1998) 874-880
19. Tarran R., Grubb B.R., Parsons D., et al. The CF salt controversy: In vivo observations and therapeutic approaches. Mol Cell 8 (2001) 149-158
20. Zhang Y., and Engelhardt J.F. Airway surface fluid volume and Cl content in cystic fibrosis and normal bronchial xenografts. Am J Physiol Cell Physiol 276 (1999) C469-C476
21. Knowles M.R., Robinson J.M., Wood R.E., et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest 100 (1997) 2588-2595
22. Joris L., Dab I., and Quinton P.M. Elemental composition of human airway surface fluid in health and diseased airways. Am Rev Respir Dis 148 (1993) 1633-1637
23. Hull J., Skinner W., Robertson C., and Phelan P. Elemental content of airway surface liquid from infants with cystic fibrosis. Am J Respir Crit Care Med 157 (1998) 10-14
24. Jayaraman S., Song Y., Vetrivel L., Shankar L., and Verkman A.S. Noninvasive in vivo fluorescence measurement of airway-surface liquid depth, salt concentration, and pH. J Clin Invest 107 (2001) 317-324
25. Effros R.M., Peterson B., Casaburi R., et al. Epithelial lining fluid solute concentrations in chronic obstructive lung disease patients and normal subjects. J Appl Physiol 99 (2005) 1286-1292
26. Jayaraman S., Song Y., and Verkman A.S. Airway surface liquid osmolality measured using fluorophore-encapsulated liposomes. J Gen Physiol 117 (2001) 423-430
27. Sisson J.H., Yonkers A.J., and Waldman R.H. Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Chest 107 (1995) 747-751
28. Thomson M.L., Pavia D., and McNicol M.W. A preliminary study of the effect of guaifenesin on mucociliary clearance from the human lung. Thorax 28 (1973) 742-747
29. Rubin B.K., Ramirez O., and Ohar J.A. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable bronchitis. Chest 109 (1996) 348-352
30. Marchette L.C., Marchette B.E., Abraham W.M., and Wanner A. The effect of systemic hydration on normal and impaired mucociliary function. Pediatr Pulmonol 1 (1985) 107-111
31. Wanner A., and Rao A. Clinical indications for and effects of bland, mucolytic and antimicrobial aerosols. Am Rev Respir Dis 122 (1980) 79-87
32. Wanner A. Clinical aspects of mucociliary transport. Am Rev Respir Dis 116 (1977) 73-125
33. Hiatt P., Eigen H., Yu P., and Tepper R.S. Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis 137 (1988) 119-122
34. Chua H.L., Collis G.G., and Le Souef P.N. Bronchial response to nebulized antibiotics in children with cystic fibrosis. Eur Respir J 3 (1990) 1114-1116
35. Middleton P.G., Geddes D.M., and Alton E.W. Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects. Thorax 48 (1993) 812-816
36. Sood N., Bennett W.D., Zeman K., et al. Increasing concentration of inhaled saline with or without amiloride: Effect on mucociliary clearance in normal subjects. Am J Respir Crit Care Med 167 (2003) 158-163
37. Talbot A.R., Herr T.M., and Parsons D.S. Mucociliary clearance and buffered hypertonic saline solution. Laryngoscope 107 (1997) 500-503
38. Mortensen J., Hansen A., Falk M., Nielsen I.K., and Groth S. Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest 103 (1993) 805-811
39. Donaldson S.H., Bennett W.D., Zeman K.L., Knowles M.R., Tarran R., and Boucher R.C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354 (2006) 241-250
40. King M., Dasgupta B., Tomkiewicz R.P., and Brown N.E. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 156 (1997) 173-177
41. Wills P.J., Hall R.L., Chan W.-M., and Cole P.J. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 99 (1997) 9-13
42. Anderson G.G., Aspedon A., Palmer K., Whiteley M., and O'Toole G. Reduction of Pseudomonas aeruginosa biofilm formation under osmotic stress. Pediatr Pulmonol S29 (2006) 319 (A317)
43. Robinson M., Regnis J.A., Bailey D.L., King M., Bautovich G.J., and Bye P.T. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 153 (1996) 1503-1509
44. Robinson M., Hemming A.L., Regnis J.A., et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 52 (1997) 900-903
45. Peatfield A.C., Richardson P.S., and Wells U.M. The effect of airflow on mucus secretion into the trachea of the cat. J Physiol 380 (1986) 429-439
46. Price A.M., Webber S.E., and Widdicombe J.G. Osmolality affects ion and water fluxes and secretion in the ferret trachea. J Appl Physiol 74 (1993) 2788-2794
47. Henke M.O., Renner A., Huber R.M., Seeds M.C., and Rubin B.K. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 31 (2004) 86-91
48. Robinson M., and Bye P.T. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol 33 (2002) 293-306
49. Eng P.A., Morton J., Douglass J.A., Riedler J., Wilson J., and Robertson C.F. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 21 (1996) 77-83
50. Elkins M.R., Robinson M., Rose B.R., et al. The National Hypertonic Saline in Cystic Fibrosis Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354 (2006) 229-240
51. Ware J., and Sherbourne C. The MOS 36-item short-form health survey: conceptual framework and item selection. Med Care 30 (1992) 473-481
52. Quittner A.L., Sweeny S., Watrous M., et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol 25 (2000) 403-414
53. Sexauer W.P., and Fiel S.B. Aerosolized antibiotics in cystic fibrosis. Semin Respir Crit Care Med 24 (2003) 717-726
54. Rodwell L.T., and Anderson S.D. Airway responsiveness to hyperosmolar saline challenge in cystic fibrosis: a pilot study. Pediatr Pulmonol 21 (1996) 282-289
55. Ballmann M., and von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J Cystic Fibrosis 1 (2002) 35-37
56. De Boeck K., Alifier M., and Vandeputte S. Sputum induction in young cystic fibrosis patients. Eur Respir J 16 (2000) 91-94
57. Henig N.R., Tonelli M.R., Pier M.V., Burns J.L., and Aitken M.L. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 56 (2001) 306-311
58. Ordonez C.L., Henig C.R., Mayer-Hamblett N., et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 168 (2003) 1471-1475
59. Suri R., Metcalfe C., Lees B., et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 358 (2001) 1316-1321
60. Elkins M.R., and Bye P.T. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med 12 (2006) 445-452
61. Anderson S.D., Brannan J.D., Spring J., et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 156 (1997) 758-765
62. Chen B.T., and Yeates D.B. Ion transport and regulation of respiratory tract fluid output in dogs. J Appl Physiol 90 (2001) 821-831
63. Wanner A., Maurer D., Abraham M.W., Szepfalusi Z., and Sielczak M. Effects of chemical mediators of anaphylaxis on ciliary function. J Allergy Clin Immunol 72 (1983) 663-667
64. Brannan J.D., Gulliksson M., Anderson S.D., Chew N., and Kumlin M. Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur Respir J 22 (2003) 491-496
65. King M., and Rubin B.K. Pharmacological approaches to discovery and development of new mucolytic agents. Adv Drug Delivery Rev 54 (2002) 1475-1490
66. Wills P.J., Chan W.M., Hall R.L., and Cole P.J. Ciliary transportability is governed by its osmolality. In: Baum G.L., Priel A., Roth Y., Liron N., and Ostfield E.J. (Eds). Cilia, mucus and mucociliary interactions (1998), Marcel Dekker Inc, New York 281-284
67. Robinson M., Daviskas E., Eberl S., Baker J., Chan H.K., Anderson S.D., and Bye P.T. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 14 (1999) 678-685
68. Azghani A.O. Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. Am J Respir Cell Mol Biol 15 (1996) 132-140
69. 1 in cystic fibrosis. J Cystic Fibrosis 5 Suppl 1 (2006) S11 A46
70. Phibbs P.V., and Eagon R.G. Transport and phosphorylation of glucose, fructose and mannitol by Pseudomonas aeruginosa. Arch Biochem Biophys 138 (1970) 470-482
71. Eagon R.G., and Phibbs P.V. Kinetics of transport of glucose, fructose and mannitol by Pseudomonas aeruginosa. Can J Biochem 49 (1971) 1031-1041
72. Ohman D.E., and Chakrabarty A.M. Utilization of human respiratory secretions by mucoid Pseudomonas aeruginosa of cystic fibrosis origin. Infect Immun 37 (1982) 662-669
73. Zabner J., Seiler M.P., Launspach J.L., et al. The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc Nat Acad Sci USA 97 (2000) 11614-11619
74. Daviskas E., and Anderson S.D. Hyperosmolar agents and clearance of mucus in the diseased airway. J Aerosol Med 19 (2006) 100-109
75. Hirsh A.J. Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Del Rev 54 (2002) 1445-1462
76. Knowles M.R., Clarke L.L., and Boucher R.C. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 325 (1991) 533-538
77. + absorption by extracellular nucleotides in human normal and cystic fibrosis airways. Am J Respir Cell Mol Biol 23 (2000) 755-761
78. + absorption in wild-type and Delta F508 CFTR-expressing human bronchial epithelia. Am J Physiol Cell Physiol 276 (1999) C827-C837
79. Kim K.C., Park H.R., Shin C.Y., Akiyama T., and Ko K.H. Nucleotide-induced mucin release from primary hamster tracheal surface epithelial cells involves the P2u purinoceptor. Eur Respir J 9 (1996) 542-548
80. Morse D.M., Smullen J.L., and Davis C.W. Differential effects of UTP, ATP, and adenosine on ciliary activity of human nasal epithelial cells. Am J Physiol Cell Physiol 280 (2001) C1485-C1497
81. Gobran L.I., Xu Z.X., Lu Z., and Rooney S.A. P2u purinoceptor stimulation of surfactant secretion coupled to phosphatidylcholine hydrolysis in type II cells. Am J Physiol Lung Cell Mol Physiol 267 (1994) L625-L633
82. 2 receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 302 (2002) 871-880
83. 2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 39 (2005) 339-348
84. Deterding R., LaVange L., Mathews D., et al. Safety and efficacy of INS37217 inhalation solution, a novel P2Y2 receptor agonist, in patients with mild cystic fibrosis: Results of a phase 2 multi-center study. Pediatr Pulmonol 38 (2004) 249 (A177)
85. Deterding R., Milla C., Barnes M.L., et al. Safety and tolerability of denufosol inhalation solution: Results of a 28-day phase 2 study in 5-7 year old patients in CF. Pediatr Pulmonol 41 (2006) 306 (A284)
86. King M., Brock G., and Lundell C. Clearance of mucus by simulated cough. J Appl Physiol 58 (1985) 1776-1782
87. King M., Zahm J.M., Pierrot D., Vaquez-Girod S., and Puchelle E. The role of mucus gel viscosity, spinnability, and adhesive properties in clearance simulated cough. Biorheology 26 (1989) 737-745
88. + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 78 (1986) 1245-1252
89. + permeability in cystic fibrosis human primary cell cultures. J Physiol 405 (1988) 77-103
90. Welsh M.J., and Liedtke C.M. Chloride and potassium channels in cystic fibrosis airway epithelia. Nature 322 (1986) 467-470
91. Hordvik N.L., Sammut P.H., Judy C.G., Strizek S.J., and Colombo J.L. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 154 (1996) 156-160
92. Balfour-Lynn I.M., and Elborn J.S. "CF asthma": what is it and what do we do about it?. Thorax 57 (2002) 742-748
93. Weinberger M. Airways reactivity in patients with CF. Clin Rev Allergy Immunol 23 (2002) 77-85
94. Mitchell I., Corey M., Woenne R., Krastins I.R., and Levison H. Bronchial hyperreactivity in cystic fibrosis and asthma. J Pediatr 93 (1978) 744-748
95. Holzer F.J., Olinsky A., and Phelan P.D. Variability of airways hyper-reactivity and allergy in cystic fibrosis. Arch Dis Child 56 (1981) 455-459
96. Landau L.I., and Phelan P.D. The variable effect of a bronchodilating agent on pulmonary function in cystic fibrosis. J Pediatr 82 (1973) 863-868
97. Balfour-Lynn I.M., Lees B., Hall P., et al., on behalf of the CF WISE (Withdrawal of Inhaled Steroids Evaluation) Investigators. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 173 (2006) 1356-1362
98. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. The Cochrane Library 2007(1).
99. Zach M.S., Oberwaldner B., Forche G., and Polgar G. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis 131 (1985) 537-543
100. Southern K.W., and Smyth R.L. Design of clinical trials in cystic fibrosis. Lancet 361 (2003) 349-350